MassBio is thrilled to join CARB-X, the new international partnership funding research to tackle the threat posed by untreatable bacterial infections.
CARB-X (www.carb-x.org) will support a suite of products through early preclinical development to a stage where they can be taken forward by private or public investment. The CARB-X partners will pool their broad scientific, technical, business and legal expertise to help grantees navigate the maze of regulatory steps, studies and data collection required for new drugs and other products to gain approval by US and/or European regulators.
MassBio will help identify promising startups working in the antimicrobial resistance field and provide business support and mentoring services to CARB-X companies as an extension of MassBio’s successful startup mentorship program, MassCONNECT. MassBio’s Chief Business Officer, John Hallinan, will represent MassBio on the CARB-X Executive Team.
MassBio will convene a CARB-X Advisory Board of industry experts to seek out and mentor companies as an extension of the successful MassCONNECT program.
WANT TO LEARN MORE?
HEAR FROM THE CARB-X LEADERSHIP TEAM:
Dr. Joe Larsen, Acting Deputy Director of the Biomedical Advanced Research Development Authority, explains how CARB-X is poised to tackle antibiotic resistance and stimulate innovation. www.PHE.gov/CARB-X
Kevin Outterson, Executive Director of CARB-X and Professor of Law at Boston University, explains the important role the antibiotics play in saving lives every day.
Antibiotic resistance is outpacing the development of new antibiotics. CARB-X is working to stimulate innovation. The Broad Institute’s Deb Hung explains how.
THE CARB-X PARTNERS:
For more information, contact MassBio's Chief Business Officer John Hallinan.